Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Dr Reddy's Q3 profit...

    Dr Reddy's Q3 profit up by 45 per cent at Rs 485 crore

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-02-03T09:45:48+05:30  |  Updated On 3 Feb 2019 9:45 AM IST
    Dr Reddys Q3 profit up by 45 per cent at Rs 485 crore

    Though Dr Reddy's was able to book a healthy profit during the quarter, revenues from North America declined by eight per cent despite new product launches.


    Hyderabad: Dr Reddy's Laboratories Ltd registered a 45 per cent increase in its profit after tax for the quarter ended December 31 at Rs 485 crore against Rs 334 crore in the third quarter of FY18, a senior official of the city-based drug maker said Friday.


    President, CFO and Global Head of HR of Dr Reddy's, Saumen Chakraborty told reporters here, consolidated revenues for the quarter under review was up by one per cent to Rs 3,850 crore.


    It was Rs 3,806 crore in the same quarter last fiscal.


    Read Also: Dr. Reddy’s gets USFDA approval for TOSYMRA for treatment of migraine


    The growth was based on improved performance in emerging markets, improved cost efficiencies and also party due to the profit booked on the sale of one of their plants here, he said.


    "It has been a good quarter. On profit, the year on year growth is 45 per cent.


    There was also profit we made out of the sale of our Jeedimetla plant," Chakraborty said in a press conference.


    Though the company was able to book a healthy profit during the quarter, revenues from North America declined by eight per cent despite new product launches.


    Revenues from North America declined by eight per cent to Rs 1,480 crore against Rs 1,607 crore in Q3 FY18.


    "In North America, the total revenue was 1,483 crore so there is a year on year decline of 8 per cent, but quarter on quarter there is a 4 per cent growth.


    Year-on-Year decline is due to the new launches we had last year.


    Read Also: Dr Reddy’s gets four observations from USFDA for Andhra plant


    They were very good launches, that's why the base was very high. We have been able to launch 10 new products in Q3 of FY 19 in North America," he said.


    Replying to query, he said the company bets big on the proposed launches of three products- Copaxone, Suboxone and birth control device Nuvaring.


    Revenues from global generics segment in Q3 was reported at Rs 3,135 crore, a year-on-year growth of four per cent over the same quarter last year, primarily driven by contributions from emerging markets and India.


    Revenues from emerging markets was at Rs 770 crore registering 31 per cent growth on year-on-year basis primarily on account of new launches, traction in new markets and improved volume off take in the existing markets.


    Revenues from India grew by 10 per cent to Rs 670 crore driven by volume traction and new products.


    Europe sales was up by one per cent to Rs 200 crore, the official said.


    Revenues from Pharmaceutical Services and Active Ingredients stood at Rs 594 crore in the third quarter with nine per cent growth over the Q2 of FY18.


    The pharma company may spend a lesser amount on CapEx this year owing to the availability of sufficient capacities.


    "We continued to improve our performance in the third quarter of FY 19, supported by significant growth in emerging markets and India, pickup in new product launches, and improvements in cost structure.


    We are on track towards delivering sustainable and profitable growth," company CEO and co-chairman G V Prasad said in a press release.


    Read Also: Dr. Reddy’s shares spike after favourable generic drug ruling

    birth control device NuvaringCEOConsolidated RevenuesCopaxoneDr ReddyDr Reddy's LaboratoriesDr. Reddy’s laboratories LtdG V PrasadHyderabadJeedimetla plantNorth AmericaNuvaRingPATSaumen ChakrabortySuboxone
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok